opioid induced respiratory depression Archives

GLP-1s Tied to Lower Risk of Substance Use Disorders

Jun 8, 2026 | General Healthcare, Nicotine Alternatives, Tobacco

A study of 142,000 patients suggests GLP-1 medications may influence brain pathways involved in cravings for nicotine, opioids, and alcohol.

Naloxone May Not Fully Reverse Respiratory Depression From Synthetic Opioids

Apr 13, 2026 | Ambulance & EMS, Emergency Room, US Pharmaceuticals

Standard doses of naloxone are often insufficient to restore normal breathing during opioid-induced respiratory depression (OIRD) after overdoses involving fentanyl and sufentanil.

Clinician Bias Linked to Opioid Stigma in Sickle Cell Care

Apr 13, 2026 | Other Chronic Diseases

Negative descriptors in clinician notes for sickle cell patients are closely associated with stigma surrounding opioid use.

Neonatal Respiratory Depression Tied to Maternal Oxycodone Use During Breastfeeding

Mar 26, 2026 | ARDS, Neonatal

A case report suggests high doses of oxycodone in breastfeeding mothers can lead to apnea and bradycardia in newborns due to immature metabolic pathways.

Gene Therapy ‘Switch’ May Offer Nonaddictive Pain Relief

Jan 9, 2026 | Clinical Trials, US Pharmaceuticals

A new gene therapy may offer pain relief without addiction, targeting only pain signals and leaving the rest of the brain untouched.

WHO: Opioid Agonist Treatment an Essential Health Service

Dec 31, 2025 | Association News, Intl' Pharmaceuticals

The World Health Organization says opioid agonist maintenance treatment (OAMT) is a cost-effective intervention that reduces mortality and morbidity.

Buprenorphine May Decrease Emergency Visits for Pregnant Women with Opioid Use Disorder

Nov 11, 2025 | Emergency Room

Pregnant women with opioid use disorder who were prescribed buprenorphine had fewer emergency department visits and hospital admissions, with the greatest benefit seen among those with 80% adherence.

New FDA Guidance on Non-Opioid Options for Chronic Pain

Sep 10, 2025 | US Pharmaceuticals

The FDA issued draft guidance to accelerate safe and effective non-opioid treatments and to reduce prescription-related opioid misuse.

FDA Mandates Changes to Opioids Labeling

Aug 4, 2025 | FDA Approvals, Healthcare & Policy, US Pharmaceuticals

The FDA is requiring safety labeling changes to all opioid pain medications to better emphasize and explain the risks associated with their long-term use.

Urgent Care Clinics Often Inappropriately Prescribe Antibiotics, Glucocorticoids, Opioids

Jul 22, 2025 | General Healthcare

Stewardship programs are needed reduce inappropriate urgent care prescribing of antibiotics, glucocorticoids and opioids.

Ai Screening for Opioid Use Disorder Tied to Fewer Hospital Readmissions

Jun 20, 2025 | Other Acute Disorders

Hospitalized adults at risk for opioid use disorder had 47% lower odds of being readmitted to the hospital within 30 days after their initial discharge if they were screened by Ai.

Using Ai to Screen Opioid Use Disorder Tied to Fewer Hospital Readmissions

Apr 28, 2025 | Emergency Room, Other Acute Disorders

A clinical trial showed that an Ai tool was as effective as healthcare providers in generating referrals to opioid use disorder addiction specialists.

Evidence Supports Buprenorphine for Acute Pain in Patients with Opioid Use Disorder

Apr 17, 2025 | Other Chronic Diseases

Continuing buprenorphine during acute pain episodes for people with opioid use disorder (OUD) may lead to lower or similar pain severity compared to discontinuation.

FDA Approves New Class of Non-Opioid Pain Medication

Feb 7, 2025 | FDA Approvals, US Pharmaceuticals

The FDA has approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults, according to the agency.

FDA Recommends Labeling Changes for Transmucosal Buprenorphine Products

Dec 30, 2024 | Recalls & Advisories, US Pharmaceuticals

The FDA issued a notice to modify labeling of buprenorphine-containing transmucosal products for the treatment of opioid dependence.

Opioid Antagonist Nalmefene Shows Comparable Effectiveness to Naloxone

Oct 31, 2024 | US Pharmaceuticals

A Purdue Pharma study explored nalmefene and naloxone for the reversal of respiratory depression induced by fentanyl in a clinical opioid-induced respiratory depression model.

Implantable Device Senses Overdose, Automatically Delivers Naloxone

Oct 23, 2024 | US Pharmaceuticals

Implanted under the skin, the Naloximeter senses dropping oxygen and sends a warning notification to a mobile app. If the user doesn’t engage with the warning message within 30 seconds, the device releases stored naloxone.

Higher Buprenorphine Doses May Reduce Emergency Care Needs for Opioid Addiction

Sep 25, 2024 | US Pharmaceuticals

An NIH-funded analysis suggests higher doses of buprenorphine were associated with lower rates of emergency department visits or use of inpatient services related to behavioral health.